1. Home
  2. GDRX vs AVLN Comparison

GDRX vs AVLN Comparison

Compare GDRX & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GoodRx Holdings Inc.

GDRX

GoodRx Holdings Inc.

HOLD

Current Price

$3.60

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

SELL

Current Price

$26.97

Market Cap

1.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
GDRX
AVLN
Founded
2011
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
GDRX
AVLN
Price
$3.60
$26.97
Analyst Decision
Hold
Strong Buy
Analyst Count
14
5
Target Price
$3.95
★ $61.80
AVG Volume (30 Days)
★ 878.1K
264.7K
Earning Date
11-03-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 125.00
N/A
EPS
★ 0.03
N/A
Revenue
★ $796,853,000.00
N/A
Revenue This Year
$0.20
N/A
Revenue Next Year
$4.72
N/A
P/E Ratio
$119.33
★ N/A
Revenue Growth
★ 0.57
N/A
52 Week Low
$1.77
$22.24
52 Week High
$4.05
$40.17

Technical Indicators

Market Signals
Indicator
GDRX
AVLN
Relative Strength Index (RSI) 60.70 49.09
Support Level $3.26 $26.81
Resistance Level $3.89 $30.45
Average True Range (ATR) 0.12 1.74
MACD 0.03 0.37
Stochastic Oscillator 91.46 81.07

Price Performance

Historical Comparison
GDRX
AVLN

About GDRX GoodRx Holdings Inc.

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: